Showing results (1-10 of 19) with videos related to
Sort By:
Pageof 2
BMJ Case Reports|September 9, 2020
<i>Nocardia farcinica</i> masquerading as intracerebral metastases in advanced metastatic prostatic cancerClaire Livings, Mayu Uemura, Reena Patel, et al.Urologic Oncology|June 11, 2015
Shifting paradigms in the estimation of survival for castration-resistant prostate cancer: A tertiary academic center experienceMehran Afshar, Felicity Evison, Nicholas D James, et al.Cancer Management and Research|December 20, 2014
Biliary stenting in advanced malignancy: an analysis of predictive factors for survivalMehran Afshar, Koudeza Khanom, Yuk Ting Ma, et al.Drug Design, Development and Therapy|January 2, 2015
Temsirolimus for patients with metastatic renal cell carcinoma: outcomes in patients receiving temsirolimus within a compassionate use program in a tertiary referral centerMehran Afshar, Jennifer Pascoe, Sue Whitmarsh, et al.Oncotarget|April 24, 2018
Non-secretion of AFP and neutrophil lymphocyte ratio as predictors for survival in hepatocellular carcinoma patients treated with sorafenib: a large UK cohortMehran Afshar, Peter Fletcher, Antonio D Bardoli, et al.Clinical Genitourinary Cancer|February 25, 2014
Sarcomatoid renal cell carcinoma: clinical outcome and survival after treatment with sunitinibVictoria Kunene, Manuela Miscoria, Sarah Pirrie, et al.Anticancer Research|February 11, 2015
Predictive factors for response to abiraterone in metastatic castration refractory prostate cancerMehran Afshar, Fawaz Al-Alloosh, Sarah Pirrie, et al.Pharmacoeconomics|February 4, 2014
Methods for identifying the cost-effective case definition cut-off for sequential monitoring tests: an extension of Phelps and MushlinRoberta Longo, Paul Baxter, Peter Hall, et al.Anticancer Research|December 25, 2016
A Study of Angiogenesis Markers in Patients with Renal Cell Carcinoma Undergoing Therapy with SunitinibClive Stubbs, Antonio D Bardoli, Mehran Afshar, et al.Cancer Investigation|July 3, 2015
Can D-Dimer Measurement Reduce the Frequency of Radiological Assessment in Patients Receiving Palliative Imatinib for Gastrointestinal Stromal Tumor (GIST)?Mehran Afshar, Patrick Hamilton, Jenny Seligmann, et al.Pageof 2